Arch Coal Appoints John Drexler COO, Matthew Giljum As CFO - Quick Facts

Arch Coal, Inc. (ARCH) said Tuesday that as part of its ongoing succession process, John Drexler will become the company's chief operating officer and Matthew Giljum will become its chief financial officer, effective April 30.

Drexler is currently Arch's CFO and Giljum is currently Arch's treasurer and vice president of finance. Both Drexler and Giljum will report to Paul Lang, Arch's incoming chief executive officer.

Drexler has served as Arch's senior vice president and CFO since 2008. Prior to that role, he held the positions of vice president of finance and accounting; vice president of accounting, reporting and planning; and director of planning and forecasting, among others. He joined Arch in 1998 after beginning his career at EY.

Giljum has served as Arch's vice president of finance and treasurer since 2015. Prior to that role, he served as the company's vice president of finance, as well as in several other positions of increasing responsibility in the company's finance department. Giljum joined the company in 2002 after beginning his career at EY.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT